131.86
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$131.84
Aprire:
$132.45
Volume 24 ore:
1.47M
Relative Volume:
0.87
Capitalizzazione di mercato:
$19.32B
Reddito:
$9.82B
Utile/perdita netta:
$1.48B
Rapporto P/E:
13.02
EPS:
10.13
Flusso di cassa netto:
$2.30B
1 W Prestazione:
+3.40%
1M Prestazione:
+6.74%
6M Prestazione:
-18.06%
1 anno Prestazione:
-43.68%
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Confronta BIIB con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
BIIB
Biogen Inc
|
131.86 | 18.69B | 9.82B | 1.48B | 2.30B | 10.13 |
![]()
LLY
Lilly Eli Co
|
765.84 | 645.82B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
153.22 | 366.76B | 89.33B | 21.81B | 18.57B | 8.99 |
![]()
ABBV
Abbvie Inc
|
187.34 | 323.41B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
NVS
Novartis Ag Adr
|
116.94 | 220.95B | 53.22B | 12.86B | 14.85B | 6.39 |
![]()
NVO
Novo Nordisk Adr
|
72.04 | 304.82B | 43.59B | 15.04B | 10.74B | 3.3766 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-28 | Downgrade | HSBC Securities | Buy → Hold |
2025-04-04 | Downgrade | Argus | Buy → Hold |
2025-02-11 | Iniziato | Bernstein | Mkt Perform |
2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
2024-12-16 | Downgrade | Stifel | Buy → Hold |
2024-12-10 | Ripresa | BofA Securities | Neutral |
2024-12-09 | Downgrade | Jefferies | Buy → Hold |
2024-11-18 | Downgrade | Needham | Buy → Hold |
2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
2024-11-14 | Iniziato | Citigroup | Neutral |
2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2024-10-10 | Ripresa | Raymond James | Mkt Perform |
2024-02-14 | Reiterato | Needham | Buy |
2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2024-01-24 | Downgrade | UBS | Buy → Neutral |
2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
2023-09-06 | Iniziato | HSBC Securities | Buy |
2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
2023-07-24 | Reiterato | UBS | Buy |
2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
2022-10-07 | Aggiornamento | Argus | Hold → Buy |
2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2022-03-08 | Downgrade | Stifel | Buy → Hold |
2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
2022-02-04 | Reiterato | Barclays | Equal Weight |
2022-02-04 | Reiterato | BofA Securities | Neutral |
2022-02-04 | Reiterato | Cowen | Outperform |
2022-02-04 | Reiterato | Morgan Stanley | Overweight |
2022-02-04 | Reiterato | Needham | Buy |
2022-02-04 | Reiterato | Oppenheimer | Outperform |
2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
2022-02-04 | Reiterato | Robert W. Baird | Neutral |
2022-02-04 | Reiterato | Wedbush | Neutral |
2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
2021-12-10 | Ripresa | Raymond James | Mkt Perform |
2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
2021-12-06 | Iniziato | Goldman | Neutral |
2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
2021-09-23 | Iniziato | Needham | Buy |
2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2021-06-14 | Reiterato | Truist | Buy |
2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
2021-06-08 | Reiterato | Barclays | Equal Weight |
2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
2021-06-08 | Reiterato | H.C. Wainwright | Buy |
2021-06-08 | Reiterato | Jefferies | Buy |
2021-06-08 | Reiterato | Morgan Stanley | Overweight |
2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
2021-06-08 | Reiterato | Stifel | Buy |
2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
2020-11-09 | Reiterato | H.C. Wainwright | Buy |
2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2020-10-28 | Iniziato | UBS | Neutral |
2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
2020-02-27 | Iniziato | Barclays | Overweight |
2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
Biogen Disappointed by INESSS Recommendation on SKYCLARYS™ and its Impact on Quebec Patients with Friedreich Ataxia – Company AnnouncementFT.com - Financial Times
Wealth Enhancement Advisory Services LLC Acquires 11,504 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Subcutaneous Biologics Market in 2025-2032 Detailed Study - openPR.com
4,772 Shares in Biogen Inc. (NASDAQ:BIIB) Purchased by First County Bank CT - MarketBeat
Czech National Bank Acquires 2,025 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Rhumbline Advisers Increases Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Acquired by GAMMA Investing LLC - MarketBeat
Biogen to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - Biogen
Relapsing Remitting Multiple Sclerosis Market Set to Witness - openPR.com
Biogen Inc (BIIB)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
Ex-Biogen Chief Medical Officer Strengthens Entrada's Duchenne Program as Phase 1 Data Shows Promise - Stock Titan
Neuromuscular Disease Therapeutics Market Growth Driven - openPR.com
152,867 Shares in Biogen Inc. (NASDAQ:BIIB) Acquired by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
What is William Blair's Estimate for Biogen Q2 Earnings? - MarketBeat
Lansforsakringar Fondforvaltning AB publ Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
City Therapeutics Partners with Biogen - Global Legal Chronicle
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Inc. (NASDAQ:BIIB) Holdings Raised by Centre Asset Management LLC - MarketBeat
California State Teachers Retirement System Buys 2,811 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Toronto Dominion Bank Has $11.11 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Lighthouse Financial LLC Acquires Shares of 2,100 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Farmers Trust Co. Acquires 2,012 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Auxier Asset Management Sells 2,136 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks - Yahoo Finance
Biogen Inc. (NASDAQ:BIIB) Shares Bought by Mackenzie Financial Corp - MarketBeat
GF Fund Management CO. LTD. Makes New $5.24 Million Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Progressive Supranuclear Palsy Treatment Market Set to Witness GrowthBiogen, AbbVie - openPR.com
PKO Investment Management Joint Stock Co Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen and City Therapeutics partner to develop RNAi therapies - MSN
Biogen Inc. (NASDAQ:BIIB) Shares Sold by USS Investment Management Ltd - MarketBeat
Siemens Fonds Invest GmbH Grows Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Public Employees Retirement System of Ohio Sells 2,866 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Voloridge Investment Management LLC Invests $23.20 Million in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $234.55 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Tauopathies Treatment Market Detailed in New Research ReportBiogen, AbbVie - openPR.com
Amyotrophic lateral Sclerosis Market 2025-2032: Top Trends & - openPR.com
Recombinant Dna Technology Market Generated Opportunities, - openPR.com
In Vitro Monoclonal Antibodies Market is expected to reach US$ - openPR.com
Biogen and City Therapeutics to develop RNAi therapy - Yahoo Finance
Biogen and City Therapeutics partner to advance RNAi therapies - World Pharmaceutical Frontiers
Biogen Inc. (NASDAQ:BIIB) Holdings Lifted by Quantinno Capital Management LP - MarketBeat
Woodline Partners LP Boosts Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s SWOT analysis: stock faces challenges amid neuroscience potential - Investing.com
Biogen’s SWOT analysis: stock faces challenges amid neuroscience potential By Investing.com - Investing.com UK
Biogen Inc. (BIIB) Taps RNAi Therapy in City Therapeutics Deal - Yahoo Finance
Biogen (NasdaqGS:BIIB) Partners With City Therapeutics in US$1 Billion RNAi Therapy Deal - simplywall.st
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):